key: cord-0967809-hq2gomuv
authors: Franchini, Massimo; Glingani, Claudia; De Donno, Giuseppe; Casari, Salvatore; Caruso, Beatrice; Terenziani, Isabella; Perotti, Cesare; Del Fante, Claudia; Sartori, Filippo; Pagani, Mauro
title: The first case of acquired hemophilia A associated with SARS‐CoV‐2 infection
date: 2020-06-03
journal: Am J Hematol
DOI: 10.1002/ajh.25865
sha: c3ed371508bea4d0cadf3b7644d545d0f5e38737
doc_id: 967809
cord_uid: hq2gomuv

nan

To the Editor:

Acquired hemophilia A (AHA) is a rare bleeding disorder caused by circulating autoantibodies directed against clotting factor VIII (FVIII). 1, 2 It involves more frequently elderly people with no previous personal or family history of bleeding. Approximately half of patients with AHA do not have underlying or predisposing disorders (idiopathic cases), with the remaining cases being associated with a wide array of conditions or diseases (ie, post-partum, autoimmune and dermatologic disorders, malignancies, infections and drugs). 3 In more than 80% of cases AHA is characterized by hemorrhage into the skin, muscles, soft tissues and mucous membranes (eg, epistaxis, gastrointestinal and urological bleeds, retroperitoneal hematomas). 3 We present here the In this case, the first reported in literature, the re-appearance of AHA was triggered by acute SARS-Cov-2 infection. This finding is particularly interesting considering the close interaction between SARS-Cov-2 and the hemostatic system. 4 The AHA cases associated with other viral infections, including hepatitis B and C viruses, have also been described. 3 The recent association between immune thrombocytopenic purpura and COVID-19 further strengthens the virus-induced immune dysregulation, 5 which could have played a key role in the pathogenesis of AHA. We therefore recommend a daily coagulation monitoring (APTT) in patients admitted with acute COVID-19 infection and the inhibitor search (through a mixing test) in those cases with otherwise unexplained onset or worsening of the hemorrhagic picture and/or aPTT prolongation.

Acquired factor VIII inhibitors

Clinical problem-solving. A bruising loss

Demographic and clinical data in acquired hemophilia A: results from the European acquired hemophilia (EACH2) registry

Hematological findings and complications of COVID-19

Immune thrombocytopenic Purpura in a patient with Covid-19

https://orcid.org/0000-0002-8795-0580